7.5% Growth in Indian Pharma Market in February, Boosted by Cardiac, GI, and Diabetes Drugs

New Delhi (The Uttam Hindu): The Indian pharmaceutical market (IPM) grew by 7.5% in February 2025, with key therapy areas such as cardiac, gastrointestinal (GI), and anti-diabetic medicines leading the growth, according to market research firm Pharmarack. The cardiac, gastrointestinal and anti-diabetic segments reported value growth of 9.5%, 9.6%, and 6%, respectively, contributing significantly to the overall IPM expansion. Additionally, the market saw a 1.5% unit growth in February.

Between March 2024 and February 2025, the moving annual turnover (MAT) for IPM grew by 8.1%, reaching over Rs 2.24 trillion, with a modest 0.6% growth in units. Cardiac, GI, and anti-infective therapies, which make up 37% of the IPM, showed strong volume growth of 10.8%, 9.6%, and 5.6%, respectively.

Notable pharmaceutical companies such as Zydus (12.7%), Torrent Pharma (11.6%), Intas (11.4%), and Sun Pharma (10.8%) registered significant monthly value growth. GSK's antibiotic Augmentin and USV’s anti-diabetic drug Glycomet GP remained the top-selling brands, with sales of Rs 817 crore and Rs 800 crore, respectively, over the last year.

Get smarter responses, upload files and images, and more.